Wall Street brokerages expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to report earnings of ($1.17) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Five Prime Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.42) and the highest estimate coming in at ($0.92). Five Prime Therapeutics posted earnings of ($1.54) per share in the same quarter last year, which indicates a positive year over year growth rate of 24%. The company is scheduled to announce its next quarterly earnings report on Monday, November 5th.
According to Zacks, analysts expect that Five Prime Therapeutics will report full year earnings of ($4.02) per share for the current financial year, with EPS estimates ranging from ($4.52) to ($3.65). For the next financial year, analysts forecast that the firm will report earnings of ($4.70) per share, with EPS estimates ranging from ($6.00) to ($3.89). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.30. Five Prime Therapeutics had a negative return on equity of 40.61% and a negative net margin of 206.02%. The company had revenue of $7.58 million for the quarter, compared to analysts’ expectations of $5.87 million.
Several brokerages have recently issued reports on FPRX. BidaskClub cut Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 26th. Leerink Swann began coverage on Five Prime Therapeutics in a research report on Thursday, September 13th. They set an “outperform” rating and a $24.00 price target on the stock. ValuEngine cut Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 28th. Wedbush lifted their price target on Five Prime Therapeutics from $17.00 to $19.00 and gave the company a “hold” rating in a research report on Friday, August 10th. Finally, Zacks Investment Research cut Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, June 27th. One research analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $31.70.
Shares of FPRX stock opened at $14.30 on Thursday. Five Prime Therapeutics has a 1 year low of $12.52 and a 1 year high of $47.63.
Several institutional investors and hedge funds have recently added to or reduced their stakes in FPRX. Xact Kapitalforvaltning AB bought a new stake in shares of Five Prime Therapeutics during the 3rd quarter worth $145,000. MetLife Investment Advisors LLC boosted its stake in shares of Five Prime Therapeutics by 48.7% during the 2nd quarter. MetLife Investment Advisors LLC now owns 19,957 shares of the biotechnology company’s stock worth $316,000 after acquiring an additional 6,535 shares in the last quarter. Alambic Investment Management L.P. bought a new stake in shares of Five Prime Therapeutics during the 2nd quarter worth $351,000. Fox Run Management L.L.C. bought a new stake in shares of Five Prime Therapeutics during the 2nd quarter worth $379,000. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Five Prime Therapeutics by 17.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 25,032 shares of the biotechnology company’s stock worth $430,000 after acquiring an additional 3,782 shares in the last quarter. 86.30% of the stock is owned by institutional investors and hedge funds.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.
Featured Story: What are CEFs?
Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.